Karl Kieburtz

6PUBLICATIONS
59CO-AUTHORS
Molecular targetsTe mātai whaipara Māori (Māori archaeology)Neurology and neuromuscular diseasesAutonomic nervous systemCognition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 20, 2026
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

M H Werner, A McGarry, C Meyer

|Jan 24, 2025
In Memoriam - Charles Warren Olanow, MD.

Karl Kieburtz, Barbara G Vickrey

|Sep 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Tien Dam, Gennaro Pagano, Michael C Brumm

|Aug 16, 2024
Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical Data.

Charles S Venuto, Konnor Herbst, Lana M Chahine

|Aug 07, 2024
LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Alpha-Synuclein Aggregates.

Lana M Chahine, David-Erick Lafontant, Seung Ho Choi

|Feb 02, 2024
Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.

Katheryn A Q Cousins, David J Irwin, Thomas F Tropea

Pageof 1

Frequent Collaborators

3 joint publications

Kathleen L Poston

3 joint publications

Andrew Siderowf

3 joint publications

Lana M Chahine

3 joint publications

Kenneth Marek